NO953146L - Biologisk aktive 3-substituerte oksindolderivater som er nyttige som antiangiogeniske midler - Google Patents
Biologisk aktive 3-substituerte oksindolderivater som er nyttige som antiangiogeniske midlerInfo
- Publication number
- NO953146L NO953146L NO953146A NO953146A NO953146L NO 953146 L NO953146 L NO 953146L NO 953146 A NO953146 A NO 953146A NO 953146 A NO953146 A NO 953146A NO 953146 L NO953146 L NO 953146L
- Authority
- NO
- Norway
- Prior art keywords
- hydrogen
- alkyl
- halogen
- tetralin
- isoquinoline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Ny anvendelse av en forbindelse av formelen: CH (D hvor Y er en bicyklisk ring valgt fra naftalen, tetralin, kinolin, isokinolin og indol; n er O eller et helt tall fra l til 3; R! er hydrogen, CpCg alkyl eller C2-C6 alkanoyl; R2 er hydrogen, halogen, Cj-Cg alkyl. cyano, karboksy, nitro eller NHR, hvor R er hydrogen eller GI-Cg alkyl: R3 er hydrogen eller Cj-Cg alkyl; R4 er hydrogen, hydroksy, Ci-Cg alkoksy, C2-Cg alkanoyloksy. karboksy, nitro eller NHR, hvor R er som definert ovenfor; R5 er hydrogen, GI-Cg alkyl eller halogen; eller et farmasøytisk akseptabelt salt derav; og hvor, når Y er naftalen. så er n O eller eller et helt tall fra l til 3, mens når Y er tetralin, kinolin, isokinolin eller indol så er n O, l eller 2; og hvor, når den bicykliske ringen Y er naftalen, kinolin, isokinolin eller indol, så kan hver av substituemene ORj, R2 og oksindolyliden uavhengig være på hvilken som helst av aryl- eller heteroarylgruppedelene i den bicykliske ringen, mens bare henzengruppedelen er substituert når Y er tetralin; og hvor, når Y er naftalen, tetralin, kinolin eller isokinolin, så er R2 hydrogen, halogen, cyano eller Cj-Cg alkyl og R3, R4 og Rf er hydrogen; mens når Y er indol så er R2 hydrogen, halogen, Cj-Cg alkyl, cyano, karboksy, nitro, eller - NHR, hvor R er som definert ovenfor, R3 er hydrogen eller Ci-Cg alkyl. R$ er hydrogen, hydroksy, Cj-Cg alkoksy, C2-Cg alkanoyloksy, karboksy, nitro eller -NHR, hvor R er som definert ovenfor, og RS er hydrogen, halogen eller Cj- Cg alkyl; som antiangiogenisk middel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939326136A GB9326136D0 (en) | 1993-12-22 | 1993-12-22 | Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents |
PCT/EP1994/003664 WO1995017181A1 (en) | 1993-12-22 | 1994-11-08 | Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
NO953146L true NO953146L (no) | 1995-08-10 |
NO953146D0 NO953146D0 (no) | 1995-08-10 |
Family
ID=10746990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO953146A NO953146D0 (no) | 1993-12-22 | 1995-08-10 | Biologisk aktive 3-substituerte oksindolderivater som er nyttige som antiangiogeniske midler |
Country Status (17)
Country | Link |
---|---|
US (1) | US5576330A (no) |
EP (1) | EP0684820B1 (no) |
JP (1) | JPH08507089A (no) |
KR (1) | KR960700707A (no) |
AT (1) | ATE204168T1 (no) |
AU (1) | AU676958B2 (no) |
CA (1) | CA2155098A1 (no) |
DE (1) | DE69427962T2 (no) |
ES (1) | ES2162871T3 (no) |
GB (1) | GB9326136D0 (no) |
HU (1) | HUT73176A (no) |
IL (1) | IL112010A (no) |
NO (1) | NO953146D0 (no) |
PL (1) | PL310379A1 (no) |
TW (1) | TW273510B (no) |
WO (1) | WO1995017181A1 (no) |
ZA (1) | ZA9410204B (no) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9501567D0 (en) * | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
US6906093B2 (en) | 1995-06-07 | 2005-06-14 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
US6147106A (en) | 1997-08-20 | 2000-11-14 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
GB9610964D0 (en) * | 1996-05-24 | 1996-07-31 | Pharmacia & Upjohn Spa | Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors |
GB9611797D0 (en) * | 1996-06-06 | 1996-08-07 | Pharmacia Spa | Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors |
GB9613021D0 (en) * | 1996-06-21 | 1996-08-28 | Pharmacia Spa | Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
WO1998024432A2 (en) * | 1996-12-05 | 1998-06-11 | Sugen, Inc. | Use of indolinone compounds as modulators of protein kinases |
JP2001513559A (ja) | 1997-08-25 | 2001-09-04 | ブレム,ハロルド | 新脈管形成インヒビターを用いる癒着および過剰な瘢痕形成の予防 |
US6531502B1 (en) | 1998-01-21 | 2003-03-11 | Sugen, Inc. | 3-Methylidenyl-2-indolinone modulators of protein kinase |
US6569868B2 (en) | 1998-04-16 | 2003-05-27 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
IL140701A0 (en) | 1998-07-13 | 2002-02-10 | Univ Texas | Cancer treatment methods using antibodies to aminophospholipids |
SI1107795T1 (en) | 1998-09-04 | 2003-06-30 | The Regents Of The University Of Michigan | Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis |
WO2000017197A1 (en) * | 1998-09-21 | 2000-03-30 | Biochem Pharma Inc. | Quinolizinones as integrin inhibitors |
JP2002532503A (ja) | 1998-12-17 | 2002-10-02 | エフ.ホフマン−ラ ロシュ アーゲー | プロテインキナーゼ阻害剤としての4,5−ピラジノオキシンドール |
KR20010101266A (ko) | 1998-12-17 | 2001-11-14 | 프리돌린 클라우스너, 롤란드 비. 보레르 | Jnk 단백질 키나제의 억제제로서의 4-아릴옥신돌 |
CN1138773C (zh) * | 1998-12-17 | 2004-02-18 | 霍夫曼-拉罗奇有限公司 | 4-链烯基(和炔基)氧吲哚作为细胞周期蛋白-依赖性激酶尤其是cdk2的抑制剂 |
US6153634A (en) * | 1998-12-17 | 2000-11-28 | Hoffmann-La Roche Inc. | 4,5-azolo-oxindoles |
US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
US6355648B1 (en) * | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
US6673843B2 (en) | 1999-06-30 | 2004-01-06 | Emory University | Curcumin and curcuminoid inhibition of angiogenesis |
US6313310B1 (en) | 1999-12-15 | 2001-11-06 | Hoffmann-La Roche Inc. | 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles |
TWI270545B (en) | 2000-05-24 | 2007-01-11 | Sugen Inc | Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
NZ522074A (en) * | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
EP1294688A2 (en) | 2000-06-02 | 2003-03-26 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
DE60134679D1 (de) * | 2000-10-20 | 2008-08-14 | Eisai R&D Man Co Ltd | Stickstoff enthaltende aromatische Heterozyklen |
AR036042A1 (es) | 2001-05-30 | 2004-08-04 | Sugen Inc | Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa |
US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
CA2478522A1 (en) * | 2002-03-08 | 2003-09-18 | Emory University | Novel curcuminoid-factor viia constructs as suppressors of tumor growth and angiogenesis |
DK1537146T3 (da) | 2002-07-15 | 2011-04-04 | Univ Texas | Antistoffer, der binder til anioniske phospholipider og aminophospholipider, og deres anvendelse til behandling af virusinfektioner |
EP1604665B1 (en) | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase inhibitor |
EP1683785B1 (en) | 2003-11-11 | 2013-10-16 | Eisai R&D Management Co., Ltd. | Urea derivative and process for producing the same |
DK1718283T3 (da) | 2004-01-22 | 2013-04-22 | Univ Miami | Topisk co-enzyme Q10 formuleringer og fremgangsmåder for anvendelse. |
ES2322175T3 (es) | 2004-09-17 | 2009-06-17 | EISAI R&D MANAGEMENT CO., LTD. | Composicion medicinal con estabilidad mejorada y gelificacion reducida. |
JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
WO2007136103A1 (ja) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
WO2008026748A1 (fr) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Agent antitumoral pour cancer gastrique non différencié |
KR101445892B1 (ko) | 2007-01-29 | 2014-09-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암 치료용 조성물 |
US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
MX2010005104A (es) | 2007-11-09 | 2010-08-04 | Peregrine Pharmaceuticals Inc | Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos. |
AU2009274512A1 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of Colorado | Clip inhibitors and methods of modulating immune function |
BR112012032462A2 (pt) | 2010-06-25 | 2016-11-08 | Eisai R&D Man Co Ltd | agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase. |
CN102115469A (zh) * | 2011-03-21 | 2011-07-06 | 浙江大学 | 吲哚啉-2-酮类衍生物的制备和用途 |
US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
MX2015004979A (es) | 2012-12-21 | 2015-07-17 | Eisai R&D Man Co Ltd | Forma amorfa de derivado de quinolina y metodo para su produccion. |
ES2687968T3 (es) | 2013-05-14 | 2018-10-30 | Eisai R&D Management Co., Ltd. | Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib |
EP2837626A1 (en) * | 2013-08-16 | 2015-02-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Indolinone derivatives as GRK5 modulators |
BR112017002827B1 (pt) | 2014-08-28 | 2023-04-18 | Eisai R&D Management Co., Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
MX2017010474A (es) | 2015-02-25 | 2017-11-28 | Eisai R&D Man Co Ltd | Metodo para suprimir el amargor de un derivado de quinoleina. |
KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
SG11201710198YA (en) | 2015-06-16 | 2018-01-30 | Eisai R&D Man Co Ltd | Anticancer agent |
US10786471B2 (en) | 2017-02-06 | 2020-09-29 | Massachusetts Institute Of Technology | Methods and products related to glutaminase inhibitors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9000950D0 (en) * | 1990-01-16 | 1990-03-14 | Erba Carlo Spa | New arylvinylamide derivatives and process for their preparation |
GB9000939D0 (en) * | 1990-01-16 | 1990-03-14 | Erba Carlo Spa | Improvement in the total synthesis of erbstatin analogs |
GB9004483D0 (en) * | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
CA2108889A1 (en) * | 1991-05-29 | 1992-11-30 | Robert Lee Dow | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
GB9115160D0 (en) * | 1991-07-12 | 1991-08-28 | Erba Carlo Spa | Methylen-oxindole derivatives and process for their preparation |
GB9127376D0 (en) * | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
AU672224B2 (en) * | 1992-08-06 | 1996-09-26 | Warner-Lambert Company | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and whichhave antitumor properties |
GB9226855D0 (en) * | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
-
1993
- 1993-12-22 GB GB939326136A patent/GB9326136D0/en active Pending
-
1994
- 1994-11-08 DE DE69427962T patent/DE69427962T2/de not_active Expired - Fee Related
- 1994-11-08 JP JP7517121A patent/JPH08507089A/ja active Pending
- 1994-11-08 WO PCT/EP1994/003664 patent/WO1995017181A1/en active IP Right Grant
- 1994-11-08 AT AT94931583T patent/ATE204168T1/de not_active IP Right Cessation
- 1994-11-08 ES ES94931583T patent/ES2162871T3/es not_active Expired - Lifetime
- 1994-11-08 PL PL94310379A patent/PL310379A1/xx unknown
- 1994-11-08 AU AU80612/94A patent/AU676958B2/en not_active Ceased
- 1994-11-08 EP EP94931583A patent/EP0684820B1/en not_active Expired - Lifetime
- 1994-11-08 CA CA002155098A patent/CA2155098A1/en not_active Abandoned
- 1994-11-08 HU HU9502761A patent/HUT73176A/hu unknown
- 1994-11-08 KR KR1019950703524A patent/KR960700707A/ko not_active Application Discontinuation
- 1994-11-15 TW TW083110552A patent/TW273510B/zh active
- 1994-12-12 ZA ZA9410204A patent/ZA9410204B/xx unknown
- 1994-12-12 US US08/354,215 patent/US5576330A/en not_active Expired - Fee Related
- 1994-12-16 IL IL11201094A patent/IL112010A/en not_active IP Right Cessation
-
1995
- 1995-08-10 NO NO953146A patent/NO953146D0/no unknown
Also Published As
Publication number | Publication date |
---|---|
IL112010A0 (en) | 1995-03-15 |
HUT73176A (en) | 1996-06-28 |
CA2155098A1 (en) | 1995-06-29 |
PL310379A1 (en) | 1995-12-11 |
JPH08507089A (ja) | 1996-07-30 |
US5576330A (en) | 1996-11-19 |
DE69427962T2 (de) | 2002-04-04 |
HU9502761D0 (en) | 1995-11-28 |
EP0684820B1 (en) | 2001-08-16 |
GB9326136D0 (en) | 1994-02-23 |
TW273510B (no) | 1996-04-01 |
IL112010A (en) | 1998-10-30 |
AU676958B2 (en) | 1997-03-27 |
AU8061294A (en) | 1995-07-10 |
EP0684820A1 (en) | 1995-12-06 |
DE69427962D1 (de) | 2001-09-20 |
NO953146D0 (no) | 1995-08-10 |
KR960700707A (ko) | 1996-02-24 |
WO1995017181A1 (en) | 1995-06-29 |
ES2162871T3 (es) | 2002-01-16 |
ZA9410204B (en) | 1995-11-10 |
ATE204168T1 (de) | 2001-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO953146L (no) | Biologisk aktive 3-substituerte oksindolderivater som er nyttige som antiangiogeniske midler | |
CA2053253A1 (en) | New aryl-and heteroarylethenylene derivatives and process for their preparation | |
CA2091058A1 (en) | Methylen-oxindole derivatives and process for their preparation | |
CA2277473A1 (en) | Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia | |
MX9504895A (es) | Derivados de beta-aril- y beta-heteroaril-alfa- cianoacrilamida n-substituidos y proceso para su preparacion. | |
HUP9902111A2 (hu) | Biciklusos aminok és N-oxidjaik, intermedierjeik, előállításuk és alkalmazásuk, a vegyületeket tartalmazó inszekticid, akaricid és nematocid készítmények | |
ATE228364T1 (de) | Indolalkaloide als antientzündliche wirkstoffe | |
MY113266A (en) | New indol derivatives derivatives with high affinity 5-ht1a receptor. | |
ZA941964B (en) | Substituted (arylalkylaminobezyl) aminopropionamide derivatives and process for their preparation | |
AU2001261707A1 (en) | Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives | |
PT96757A (pt) | Processo de preparacao de derivados de indolo e de composicoes farmaceuticas | |
NZ291855A (en) | Bridged azabicyclo-piperazin-1-yl-2-phenyl-butan-1-one derivatives as 5-ht1a antagonists | |
IE802682L (en) | Oxazoline derivatives | |
AU3773397A (en) | Method for preparing halogenated 2-amino or 2-acetamido trifluoromethylbenzene derivatives | |
ES8505370A1 (es) | Procedimiento para preparar nuevos compuestos heterociclicos |